Evidence map›Paper›PMID 24005764›Full record

ArticleHeart and vessels2014

Resolution of a left ventricular thrombus by the thrombolytic action of dabigatran.

Yasutsugu Nagamoto, Tetsuya Shiomi, Taku Matsuura, Arihide Okahara, Kaoru Takegami, Daigo Mine, Takaharu Shirahama, Yasuaki Koga, Keiki Yoshida, Kenji Sadamatsu and 1 more

2 registry-linked trialsAbstract readCase Reports
PubMed Publisher
In one paragraph

Article in Heart and vessels, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03764241 phase3unknown statusnot on this mapstarted 2020, after this paper: background citation

Efficacy and Safety of Anticoagulant on Early Treatment of Post-STEMI Left Ventricular Thrombus: an Open, Prospective, Randomized and Multi-centers Trial.

TypeinterventionalSponsorRenJi HospitalRan2020 to 2023Enrolled280ConditionsST Segment Elevation Myocardial Infarction, Left Ventricular ThrombusArmsRivaroxaban, Vitamin K Antagonist
NCT03786757 phase3unknown statusnot on this mapstarted 2019, after this paper: background citation

Efficacy and Safety of Anticoagulant on Early Prevention of Post-STEMI Left Ventricular Thrombus: an Open, Prospective, Randomized and Multi-centers Trial.

TypeinterventionalSponsorRenJi HospitalRan2019 to 2022Enrolled200ConditionsST Segment Elevation Myocardial Infarction, Left Ventricular ThrombusArmsRivaroxaban
3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. The role of rivaroxaban in left ventricular thrombi.Anatolian journal of cardiology · 2019
    Article
  11. Article
  12. Article
  13. Article
  14. Challenges in management of left ventricular thrombus.Therapeutic advances in cardiovascular disease · 2017
    Review
  15. Article
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yasutsugu NagamotoDivision of Cardiology, Saga Prefectural Hospital Koseikan, 1-12-9, Mizugae, Saga city, 840-8571, Japan, sqopacificsouthern1978@yahoo.co.jp.
Tetsuya Shiomi
Taku Matsuura
Arihide Okahara
Kaoru Takegami
Daigo Mine
Takaharu Shirahama
Yasuaki Koga
Keiki Yoshida
Kenji Sadamatsu
Kiyoshi Hayashida

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 77-year-old man was referred to our cardiovascular department for detailed examination after abnormal electrocardiography findings were obtained during a preoperative cataract surgery workup. Ultrasound echocardiography (UCG) and computed tomography (CT) revealed evidence of previous myocardial infarction with anteroseptal akinesis and a left ventricular (LV) thrombus (14 × 12 mm). Dabigatran (220 mg/day) was prescribed as an outpatient treatment, and the disappearance of the LV thrombus was confirmed by UCG and CT 27 days after dabigatran initiation. No thromboembolism occurred between treatment initiation and thrombus resolution. Our results indicate that dabigatran has thrombolytic action on an acute pre-existing intracardiac thrombus.

Indexed as

Thrombolytic TherapyAgedBenzimidazolesbeta-AlanineDabigatranFibrinolytic AgentsHeart DiseasesHeart VentriclesHumansIncidental FindingsMalePredictive Value of TestsThrombosisTime FactorsTomography, X-Ray ComputedTreatment OutcomeBenzimidazolesbeta-AlanineDabigatranFibrinolytic Agents

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.